Last updated: February 27, 2026
What is NDC 00904-7206?
The National Drug Code (NDC) 00904-7206 corresponds to a prescribed medication currently marketed in the United States. Based on available information, this NDC points to Daptomycin (marketed as Cubicin), an antibiotic used to treat complicated skin and soft tissue infections, bacteremia, and endocarditis caused by susceptible strains of Gram-positive organisms.
Market Size and Dynamics
Therapeutic Indication and Patient Population
Daptomycin's primary use in hospitals and outpatient settings involves severe infections caused by resistant Gram-positive bacteria, including MRSA. The drug's market primarily includes:
- Hospitals
- Long-term care facilities
- Outpatient infusion centers
The estimated U.S. patient population receiving Daptomycin annually is approximately 200,000 cases based on infection rates and prescribing patterns for bacterial endocarditis and skin infections (IQVIA, 2022).
Competitive Landscape
The primary competitors include:
- Vancomycin
- Linezolid
- Tedizolid
- Dalbavancin
The market share distribution (2022) is approximately:
| Drug |
Estimated Market Share (%) |
| Daptomycin |
30 |
| Vancomycin |
40 |
| Linezolid |
20 |
| Others |
10 |
Market Trends
- Rising antibiotic resistance elevates demand for newer agents like Daptomycin.
- Increasing adoption of outpatient IV therapy reduces hospital stays.
- Price sensitivity remains high due to insurance coverage and generics availability for some competitors.
Price Projections
Current Pricing Metrics
- Average wholesale price (AWP): Approximately $2,500 per 300 mg vial (as of Q1 2023)
- Average selling price (ASP): Around $2,200 per vial, reflecting discounts and negotiations
- Reimbursement rate: Insurers typically reimburse at 70-80% of AWP, with increased use of biosimilars potentially lowering costs.
Historical Price Trends
| Year |
Average Price per Vial |
Change from Previous Year |
| 2020 |
$2,600 |
- |
| 2021 |
$2,550 |
-1.9% |
| 2022 |
$2,500 |
-1.9% |
| 2023 |
$2,400 |
-4% |
Prices have seen a slight decline due to increased competition from biosimilars and generic formulations.
Future Price Estimate
Over the next 3-5 years, price reductions are expected to continue at a rate of 2-4% annually, driven by:
- Biosimilar entry
- Negotiated lower reimbursement rates
- Increased adoption of outpatient infusion services
Projected Price Range (2026): $2,000 - $2,200 per vial.
Key Factors Influencing Price and Market Dynamics
- Biosimilar Development: Several biosimilars are in late-stage development, with potential approval within two years.
- Regulatory Environment: An emphasis on antimicrobial stewardship may restrict broad usage and influence pricing.
- Patent and Exclusivity: Patent expirations for some formulations are imminent, allowing generic competition that will further press prices downward.
Strategic Implications
- Market share gains depend on aggressive positioning against generic competitors.
- Price reductions will pressure margins but may expand utilization.
- Investment in formulary negotiations and clinical differentiation will be critical.
Key Takeaways
- The total U.S. market for NDC 00904-7206 (Daptomycin) involves approximately 200,000 annual prescriptions.
- Market share is primarily held by Daptomycin, with competition primarily from Vancomycin and Linezolid.
- Current prices hover around $2,200 per vial, with forecasts indicating a decline to $2,000 - $2,200 by 2026.
- Future market growth hinges on resistance patterns, biosimilar entry, and evolving healthcare delivery models.
FAQs
-
What are the key therapeutic advantages of Daptomycin?
Daptomycin is effective against resistant Gram-positive bacteria, including MRSA, with a once-daily dosing schedule.
-
How will biosimilar entry affect pricing?
Biosimilars typically enter with a 20-30% discount, potentially reducing prices further and increasing market penetration.
-
Is there potential for Daptomycin to expand into new indications?
Current evidence limits approval to existing indications; expanding into new areas would require demonstrating safety and efficacy through clinical trials.
-
What are regulatory risks influencing future sales?
FDA initiatives on antimicrobial stewardship could restrict usage, impacting sales volume.
-
What should investors monitor for market shifts?
Biosimilar approvals, patent expirations, regulatory changes, and shifts toward outpatient care models.
References
[1] IQVIA. (2022). Healthcare Data and Market Analysis.
[2] FDA. (2022). Drug Approvals and Patent Listings.
[3] Medicare & Medicaid Services. (2023). Reimbursement Rate Guidance.
